SECURE Trial: Stress Echocardiography With Carotid Ultrasound vs Routine CT Coronary Angiography in Chronic Coronary Syndrome for Endpoints

NCT ID: NCT06185530

Last Updated: 2025-11-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 2000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-09-18
• Study Completion Date: 2031-12-31

Brief Summary

Diseases of the heart and circulation are known as cardiovascular diseases, and they cause over 160,000 deaths each year.

Coronary heart disease (CHD) is the most common cardiovascular disease. This is due to a build-up of fatty material, known as atherosclerosis, in the blood vessels supplying blood to the heart muscle. This can cause chest pain or if blocked, can cause a heart attack.

Two of the main non-invasive tests to look for coronary heart disease are Computed Tomography Coronary Angiography (CTCA) and Stress Echocardiography (Ultrasound scan).

CTCA shows the arteries and allows small amounts of disease to be seen that may not yet be causing any symptoms. However, if there's lots of disease and calcification, it becomes difficult to tell how severe it is, which means several tests may be needed. Stress Echocardiography shows if enough blood is reaching the heart muscle, so can show if there is severe disease that needs treatment. However, it can't see the arteries so doesn't showt small disease that may benefit from tablet treatment. There is not yet an effective non-invasive combined test that can give all this information in one go.

Studies have shown that if there's atherosclerosis in another artery, a person is very likely to have coronary atherosclerosis as well. Carotid atherosclerosis, in the neck arteries, can be seen with ultrasound similar to stress echocardiography. So, by combining these two tests the investigators want to see if it is possible to see severe as well as small areas of disease in one test, to provide better treatment.

The study will enrol 2,000 participants, who need investigation for CHD, equally randomised to CTCA or stress echocardiography with carotid ultrasound. We will follow these participants for 5 years and observe for any adverse outcomes and ask them to complete a questionnaire.

Conditions

Chronic Coronary Syndrome; Coronary Disease; Coronary Artery Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Participants undergo the cardiac tests: stress echocardiography with carotid ultrasound

Group Type: EXPERIMENTAL

Detection of obstructive coronary disease

Intervention Type: DIAGNOSTIC_TEST

Detection of obstructive coronary disease

Participants undergo the cardiac test: CT coronary angiography

Group Type: ACTIVE_COMPARATOR

Detection of obstructive coronary disease

Intervention Type: DIAGNOSTIC_TEST

Detection of obstructive coronary disease

Interventions

Detection of obstructive coronary disease

Detection of obstructive coronary disease

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

1. Age > 18 years old

2. Patients referred to RACPC and judged by the reviewer to require a further imaging investigation, either SE or CTCA, to evaluate a suspected diagnosis of CAD

3. AND

1. Have a PTP score ≥ 5%, as calculated using ESC guidelines OR

2. Have clinical history in keeping with 'typical' angina symptoms, as judged by the investigator, in patients with a PTP score <5% - With 'typical' symptoms, as per ESC guidelines, being all three of the following

i) Constricting symptoms in the front of the chest or in the neck, jaw, shoulder or arm ii) Precipitated by physical exertion iii) Relieved by rest or nitrates within 5 minutes

4. Able to give informed consent to participate in the study and its follow up

Exclusion Criteria

1. Patients with diagnosed ACS that require urgent or emergency treatment or hospitalisation for inpatient investigations.

2. Known history of obstructive CAD (Previous MI, PCI or CABG) or previous invasive angiography with evidence of ≥ 50% stenosis in any epicardial vessel.

3. Patients who have undergone invasive or non-invasive, functional or anatomical (Including CAC score) testing for detection of CAD within the previous 1 year of clinical assessment.

4. Documented allergy to iodinated contrast or documented allergy to both ultrasound contrasts used at LNWH Trust; Luminity® (Perflutren) and SonoVue® (Sulphur Hexafluoride) or the constitutes

5. Contraindications to undergoing CTCA, including but not limited to;

• eGFR < 40 ml/min
• Contraindications to beta-blockers including but not limited to, documented allergy or significant airways disease in the judgement of the investigator.
• Exceeding CT scanner weight tolerance

6. Contraindications to undergoing SE, including but not limited to;

• Known cardiomyopathic process (Hypertrophic cardiomyopathy (HCM)) with resting gradient > 50mmHg or severe valvular lesion
• Severe uncontrolled hypertension (≥180/100mmHg)

7. Known pregnancy

8. Unable to provide informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

London North West Healthcare NHS Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Prof Roxy Senior

Role: PRINCIPAL_INVESTIGATOR

LNWH Trust

Locations

London North West University Healthcare NHS Trust

Harrow, Middx, United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Emma Howard

Role: CONTACT

emma.howard16@nhs.net

0208 869 2548

Facility Contacts

Sunder Chita

Role: primary

sunderchita@nhs.net

Ann Banfield

Role: backup

annbanfield@nhs.net

Other Identifiers

CRC/2023/001

Identifier Type: -

Identifier Source: org_study_id